Astrazeneca (AZN) Change in Cash (2009 - 2026)

Astrazeneca's Change in Cash history runs 16 years deep, the most recent figure standing at -$6.5 billion for Q2 2026.

• In Q2 2026, Change in Cash fell 67.6% year-over-year to -$6.5 billion; the TTM figure through Jun 2026 stood at -$2.1 billion (down 723.1% YoY), while the FY2025 annual figure was $223.0 million, up 293.91% from the prior year.
• Change in Cash for Q2 2026 stood at -$6.5 billion, down from $5.7 billion in the prior quarter.
• The five-year high for Change in Cash was $6.1 billion in Q2 2023, with the low at -$6.5 billion in Q2 2026.
• The 5-year median for Change in Cash is -$410.0 million (2022), against an average of $268.8 million.
• The sharpest annual moves came in 2022 and 2024: Change in Cash plunged 253.55% in 2022, then surged 4014.58% in 2024.
• Astrazeneca's Change in Cash stood at -$847.0 million in 2022, then jumped by 823.38% to $6.1 billion in 2023, then tumbled by 193.88% to -$5.8 billion in 2024, then gained by 9.49% to -$5.2 billion in 2025, then declined by 24.91% to -$6.5 billion in 2026.
• Business Quant data shows AZN's Change in Cash at -$6.5 billion in Q2 2026, $5.7 billion in Q1 2026, and -$5.2 billion in Q4 2025.